miR-148b参与调控弥漫性大B细胞淋巴瘤药物敏感性的机制

doi:10.3969/j.issn.2095-9400.2020.01.003

Abstract
Figure/Table
References (0)
Related Citation (2)

Download: PDF (2038 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the functional role of miR-148b in regulating chemosensitivity in diffuse large B-cell lymphoma (DLBCL) by targeting Ezrin protein. Methods: After the human DLBCL resistant cell line CRL2631/CHOP was induced, the expression of miR-148b in CRL2631 cells and CRL2631/CHOP cells was observed by real-time fluorescent quantitative PCR and the difference of Ezrin protein expression between the two groups was measured by Western blot. Double luciferase test was performed to detect the targeted binding between miR-148b and Ezrin. Sensitivity of CRL2631/CHOP cells and CRL2631 cells to CHOP was determined by microRNAs simulation/interference technique and CCK-8 method. Results: The expression level of miR-148b in CRL2631/CHOP cells was significantly lower than that in CRL2631 cells (P=0.001). The expression level of Ezrin protein in CRL2631/CHOP cells was obviously higher than that in CRL2631 cells (P<0.05). The results of the double luciferase assay indicated that Ezrin was a direct target gene of miR-148b. The expression of Ezrin and MDR-1 protein in CRL2631/CHOP cells transfected with miR-148b mimic were down regulated (P<0.05) and the sensitivity of transfected CRL2631/CHOP cells to CHOP was strengthened (P<0.05). Furthermore, the expression of Ezrin and MDR-1 protein transfected with miR-148b inhibitor in CRL2631 cells were up-regulated with the sensitivity to CHOP diminished (P<0.05). Conclusion: miR-148b regulates the chemosensitivity of DLBCL cells to CHOP by targeting Ezrin.

Key words： diffuse large B-cell lymphoma miR-148b Ezrin CHOP chemosensitivity

Received: 08 March 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Xiaoji
	FANG Weiyue
	DONG Yuqing
	SUN Ni
	SU Tong
	YANG Xiangchou
	GUO Wenjian
	HE Muqing
	YAO Rongxin

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2020.01.003 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I1/12

[1] A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project[J]. Blood, 1997, 89(11): 3909-3918.
[2] 肖畅, 苏祖兰, 吴秋良, 等. 根据WHO新分类对493例非霍奇金淋巴瘤的临床病理分析[J]. 中华病理学杂志, 2005, 34(1): 22-27.
[3] FISHER R I, GAYNOR E R, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lym-phoma[J]. N Engl J Med, 1993, 328(14): 1002-1006.
[4] SUI C, MENG F, LI Y, et al. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1 (DNMT1) ex-pression[J]. J Transl Med, 2015, 13: 132.
[5] WU Y, LIU G L, LIU S H, et al. MicroRNA-148b enhances the radiosensitivity of non-Hodgkin’s Lymphoma cells by promoting radiation-induced apoptosis[J]. J Radiat Res, 2012, 53(4): 516-525.
[6] LIU Y, ZENG L, ZHANG S, et al. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods[J]. Med Oncol, 2013, 30(2): 528.
[7] MAXWELL S A, LI Z, JAYE D, et al. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen[J]. J Biol Chem, 2009, 284(33): 22379-22389.
[8] 周欢栋, 顾睿, 吴大洲, 等. TGFβR3基因3’UTR双荧光素酶报告载体的构建及其与miR-let-7a靶向关系的验证[J]. 温州医科大学学报, 2017, 47(5): 313-317.
[9] CHAN J K. The new World Health Organization classification of lymphomas: the past, the present and the future[J]. Hematol Oncol, 2001, 19(4): 129-150.
[10] BAI H, WEI J, DENG C, et al. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen[J]. Int J Hematol, 2013, 97(2): 223-231.
[11] KIM J, JEONG D, NAM J, et al. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma[J]. Gene, 2015, 558(1): 173-180.
[12] MARQUES S C, RANJBAR B, LAURSEN M B, et al. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma[J]. Exp Hematol, 2016, 44(4): 238-246.
[13] YUAN W X, GUI Y X, NA W N, et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients[J]. Oncol Lett, 2016, 11(1): 423-432.
[14] LEIVONEN S K, ICAY K, JÄNTTI K, et al. MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma [J]. Blood Cancer J, 2017, 7(12): 654.
[15] HAFLIDADÓTTIR B S, BERGSTEINSDÓTTIR K, PRAETORIUS C, et al. miR-148 regulates Mitf in melanoma cells[J]. PLoS One, 2010, 5(7): e11574.
[16] MOU Z, XU X, DONG M, et al. MicroRNA-148b acts as a tumor suppressor in cervical cancer by inducing G1/S-phase cell cycle arrest and apoptosis in a caspase-3-dependent manner[J]. Med Sci Monit, 2016, 22: 2809-2815.
[17] SHEN J, HU Q, SCHRAUDER M, et al. Circulating miR-148b and miR-133a as biomarkers for breast cancer detection[J]. Oncotarget, 2014, 5(14): 5284-5294.
[18] WANG R, YE F, ZHEN Q, et al. MicroRNA-148b is a potential prognostic biomarker and predictor of response to radiotherapy in non-small-cell lung cancer[J]. J Physiol Biochem, 2016, 72(2): 337-343.
[19] HUMMEL R, WATSON D I, SMITH C, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells[J]. J Gastrointest Surg, 2011, 15(3): 429-438.
[20] VALDMAN A, FANG X, PANG S T, et al. Ezrin expression in prostate cancer and benign prostatic tissue[J]. Eur Urol, 2005, 48(5): 852-857.
[21] GAVERT N, BEN-SHMUEL A, LEMMON V, et al. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells[J]. J Cell Sci, 2010, 123(Pt 12): 2135-2143.
[22] LV X G, JI M Y, DONG W G, et al. EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways[J]. Mol Med Rep, 2012, 5(5): 1220-1226.
[23] SAYGIDEĞER-KONT Y, MINAS T Z, JONES H, et al. Ezrin enhances EGFR signaling and modulates erlotinib sensitivity in non-small cell lung cancer cells[J]. Neoplasia, 2016, 18(2): 111-120.
[24] CHEN Q Y, XU W, JIAO D M, et al. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro[J]. Mol Cell Biochem, 2013, 377(1-2): 207-218.
[25] PORE D, BODO J, DANDA A, et al. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma[J]. Leukemia, 2015, 29(9): 1857-1867.
[26] MAXWELL S A, CHERRY E M, BAYLESS K J. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2011, 52(5): 849-864.